At the time of writing, BridgeBio Pharma Inc [BBIO] stock is trading at $55.49, up 1.28%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 4.98% over the last week, with a monthly amount glided 5.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $66. On July 14, 2025, Jefferies initiated with a Buy rating and assigned a price target of $70 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $60 on July 09, 2025. Wolfe Research initiated its recommendation with a Outperform and recommended $49 as its price target on June 17, 2025. Redburn Atlantic started tracking with a Buy rating for this stock on March 31, 2025, and assigned it a price target of $50. In a note dated October 16, 2024, Scotiabank initiated an Sector Outperform rating.
For the past year, the stock price of BridgeBio Pharma Inc fluctuated between $21.72 and $55.33. Currently, Wall Street analysts expect the stock to reach $71 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $55.49 at the most recent close of the market. An investor can expect a potential return of 27.95% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
According to BridgeBio Pharma Inc [NASDAQ:BBIO], the company’s sales were 235.81M for trailing twelve months, which represents an 4999.86% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -2.78%, Pretax Profit Margin comes in at -3.31%, and Net Profit Margin reading is -3.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is 0.51 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.5.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that BridgeBio Pharma Inc [NASDAQ:BBIO] has a current ratio of 5.19. As well, the Quick Ratio is 5.08, while the Cash Ratio is 4.26. Considering the valuation of this stock, the price to sales ratio is 44.99.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Oct 09 ’25 when 40000.0 shares were sold. Chief Executive Officer, Kumar Neil completed a deal on Oct 08 ’25 to sell 40000.0 shares. Meanwhile, Director KUMAR HALDEA FAMILY IRREVOCABL bought 0.12 million shares on Oct 08 ’25.
